María del Mar CastroJoelle RodePaulo Roberto Lima MachadoAlejandro Llanos‐CuentasMárcia HuebGláucia CotaIsis Valentina RojasYenifer OrobioOscar Oviedo SarmientoErnesto Rojas2026-03-222026-03-22202310.1371/journal.pntd.0011029https://doi.org/10.1371/journal.pntd.0011029https://andeanlibrary.org/handle/123456789/43781Citaciones: 34Our findings support the need for greater availability and use of alternatives to systemic antimonials, particularly local therapies, and development of strategies to improve patient follow-up across the region, with special attention to pediatric populations.enMedicineAdverse effectMiltefosinePediatricsRetrospective cohort studyRegimenMeglumine antimoniateClinical trialYoung adultInternal medicinearticle